Updated information on COVID-19 and Flu: Restricted visitation is now in effect
Category
Cancer
Sub Category
Metastatic Breast
Study Name
POL6326-009: An International, Phase 3, Muticenter, Randomized, Open-Label Trial Comparing Balixafortide in combination with Eribulin versus Eribulin alone in Patients with HER2 negative, Locally Recurrent or Metastatic Breast Cancer
Principal Investigator
Gordan Srkalovic
Study Information
https://clinicaltrials.gov/ct2/results?cond=&term=NCT03786094&cntry=&state=&city=&dist=
Contact for Questions
Clinical Trials Office – 517.364.9400

Site view: at a glance